Latest News

STAT Plus: Clovis Oncology pays $20 million to settle charges of misleading investors

Clovis Oncology (CLVS), its chief executive, and a former chief financial officer will collectively pay more than $20 million to settle civil charges of misleading investors about a lung cancer drug that was being developed.

During a four-month period beginning in July 2015, the drug maker and chief executive Patrick Mahaffy made various misleading statements about the effectiveness of its rociletinib drug compared with another treatment. Specifically, investor presentations, press releases, and regulatory filings boasted the drug demonstrated a 60 percent patient response rate.

Continue to STAT Plus to read the full story…

Source link

Related posts

MC2 Therapeutics A/S voltooit inschrijving van EU Fase 3 directe vergelijkende studie bij patiënten met plaque psoriasis behandeld met MC2-01 PAD™ Cream


Medical News Today: What are the best diets for ADHD?


People with acquired paralysis later in life report higher rates of depression, anxiety


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy